Comparative Pharmacology
Head-to-head clinical analysis: KEFZOL versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFZOL versus VELOSEF 125.
KEFZOL vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic